A Psychedelic Ban Would Disrupt Important Research – Reason

We are grateful for Reason for shining light on our court case with the DEA, fighting to keep DOI & DOC, two psychedelic research chemicals from becoming Schedule I drugs.

SSDP describes the two compounds as “essential research chemicals in pre-clinical psychiatry and neurobiology,” noting that their unscheduled status has made them accessible as tools for studying serotonin receptors. It says DOI, in particular, has been “a cornerstone in neuroscience research” due to its selectivity for the 5-HT2A serotonin receptor, crucial for understanding the therapeutic effects of psychedelics. Scientists have used DOI to “map the localization of an important serotonin receptor in the brain critical in learning, memory, and psychiatric disease,” SSDP notes, and DOI studies “have shown encouraging results in managing pain and reducing opioid cravings.”

Read the article here.